outbreak
emerg
infecti
diseas
caus
pathogen
sar
coronaviru
recent
influenza
virus
associ
signific
mortal
morbid
human
neutral
antibodi
individu
recov
infect
confer
therapeut
protect
other
infect
pathogen
howev
survivor
may
alway
avail
provid
plasma
clone
monoclon
antibodi
mab
genom
immunoglobulin
gene
rhesu
macaqu
human
highli
homolog
therefor
investig
whether
neutral
mab
highli
homolog
human
humanlik
could
gener
use
influenza
viru
model
first
immun
rhesu
macaqu
recombin
adenovirus
carri
synthet
gene
encod
hemagglutinin
ha
follow
screen
antibodi
phage
display
librari
deriv
b
cell
immun
monkey
clone
select
macaqu
immunoglobulin
heavi
chain
light
chain
variabl
region
human
igg
constant
region
gener
humanmacaqu
chimer
mab
exhibit
homolog
human
antibodi
select
mab
demonstr
potent
neutral
activ
three
clade
influenza
virus
vivo
protect
experi
demonstr
mab
effect
protect
mice
even
administ
day
infect
influenza
viru
particular
mab
demonstr
subpicomolar
bind
affin
ha
superior
vivo
protect
efficaci
without
loss
bodi
weight
obviou
lung
damag
analysi
escap
mutant
demonstr
antibodi
bound
conserv
epitop
region
contain
two
amino
acid
globular
head
ha
studi
demonstr
gener
neutral
mab
potenti
applic
human
urgent
prepared
outbreak
new
influenza
infect
virul
infecti
diseas
outbreak
infecti
diseas
sever
acut
respiratori
syndrom
sar
epidem
sever
influenza
pandem
especi
recent
emerg
case
caus
loss
human
life
public
panic
econom
setback
vaccin
specif
pathogen
effect
mean
protect
human
infect
howev
take
mani
year
even
decad
research
develop
manufactur
vaccin
emerg
pathogen
prepared
new
pandem
outbreak
virul
infecti
diseas
challeng
demand
public
health
shown
individu
recov
viral
infect
gener
neutral
antibodi
pathogen
plasma
confer
therapeut
protect
infect
individu
administ
passiv
howev
plasma
convalesc
individu
may
avail
suffici
quantiti
may
nonexist
survivor
futur
pandem
new
emerg
infecti
diseas
therefor
method
rapidli
gener
select
neutral
antibodi
urgent
need
defens
new
virul
pathogen
although
monoclon
antibodi
gener
mice
immun
specif
antigen
hybridoma
technolog
immunogen
nonhuman
antibodi
requir
human
prolong
laborintens
process
screen
naiv
synthet
antibodi
phage
display
librari
human
origin
lead
identif
humanlik
mab
howev
concern
regard
lack
vivo
matur
target
antigen
obtain
optim
neutral
antibodi
exhibit
high
affin
potenc
sever
method
report
neutral
mab
clone
infect
vaccin
individu
use
singl
b
cell
clone
phage
display
howev
human
survivor
may
avail
everi
outbreak
ethic
legal
issu
associ
use
human
subject
immun
individu
pathogen
antigen
especi
approv
vaccin
avail
genom
immunoglobulin
gene
rhesu
macaqu
share
homolog
human
gener
humanlik
mab
rhesu
macaqu
immun
target
antigen
studi
use
influenza
viru
model
pathogen
demonstr
integr
solut
gener
high
affin
neutral
mab
around
ident
human
immunoglobulin
highli
pathogen
avian
influenza
viru
exhibit
high
mortal
rate
human
given
absenc
immun
human
popul
concern
possibl
catastroph
influenza
pandem
viru
gain
humantohuman
transmiss
abil
two
class
antivir
drug
use
earli
intervent
treat
influenza
viral
infect
neuraminidas
na
inhibitor
oseltamivir
zanamivir
inhibit
viral
matur
spread
ion
channel
blocker
amantadin
rimantadin
block
viral
proton
channel
inhibit
viral
uncoat
entri
howev
drug
effect
use
earli
stage
infect
increas
report
resist
drug
studi
use
mous
model
clinic
observ
indic
neutral
antibodi
may
provid
better
therapeut
efficaci
exist
antivir
drug
even
later
stage
infect
studi
demonstr
integr
process
follow
use
recombin
adenovir
vector
carri
synthet
gene
encod
target
antigen
allow
rapid
prepar
antigen
without
need
pathogen
hand
immun
rhesu
macaqu
macaca
mulata
vector
antigen
pathogen
avail
screen
antibodi
phage
display
librari
deriv
b
cell
harvest
immun
macaqu
clone
macaqu
immunoglobulin
heavi
chain
light
chain
variabl
region
combin
human
constant
region
gener
humanmacaqu
chimer
mab
character
mab
use
vitro
vivo
studi
studi
demonstr
practic
option
rapid
gener
neutral
mab
potenti
applic
human
prepared
outbreak
new
influenza
virul
infecti
diseas
immun
adenoviru
carri
codonoptim
gene
encod
ha
induc
neutral
antibodi
influenza
virus
rhesu
macaqu
gener
immun
requir
collect
manipul
target
pathogen
prepar
relat
antigen
immun
pandem
pathogen
may
avail
biosafeti
transport
technolog
issu
even
social
polit
barrier
earlier
studi
lab
other
shown
adenovirusmedi
deliveri
antigen
includ
influenza
ha
induc
robust
antibodi
respons
within
short
period
immun
studi
first
synthes
three
hemagglutinin
ha
gene
base
human
codon
usag
optim
express
mammalian
cell
next
construct
three
recombin
replicationincompet
adenovirus
carri
fulllength
ha
gene
repres
three
differ
clade
virus
includ
ahong
clade
clade
azh
clade
respect
adenovir
vectormedi
express
ha
protein
confirm
use
western
blot
analysi
cell
lysat
reveal
express
cleavag
figur
immun
two
rhesu
macaqu
mixtur
viral
particl
week
via
intramuscular
inject
variou
interv
serum
sampl
collect
detect
neutral
antibodi
differ
clade
virus
microneutr
mn
assay
use
monitor
kinet
neutral
antibodi
recombin
influenza
virus
carri
three
ha
clade
backbon
influenza
virus
respect
neutral
antibodi
detect
week
initi
immun
level
increas
week
continu
increas
week
week
follow
addit
immun
neutral
antibodi
maintain
high
level
least
week
sera
collect
macaqu
week
neutral
three
clade
recombin
virus
influenza
viru
figur
western
blot
analysi
confirm
presenc
serum
antibodi
bound
three
clade
virus
test
viru
figur
data
demonstr
adenovirusmedi
express
ha
effect
elicit
product
neutral
antibodi
ha
protein
rhesu
macaqu
earli
two
week
immun
mrna
extract
peripher
blood
mononuclear
cell
pbmc
immun
macaqu
use
construct
antibodi
phage
librari
display
singlechain
variabl
fragment
scfv
contain
immunoglobulin
variabl
region
heavi
chain
vh
light
chain
vl
base
publish
data
regard
rhesu
immunoglobulin
gene
closest
correspond
human
immunoglobulin
gene
use
pcr
amplifi
vh
vl
cdna
deriv
b
cell
pcr
product
use
construct
scfvpresent
phage
librari
macaqu
librari
contain
approxim
x
clone
phage
librari
one
macaqu
subject
round
pan
use
recombin
protein
target
antigen
elisa
screen
use
inactiv
recombin
influenza
virus
result
isol
clone
base
analysi
vh
sequenc
scfv
clone
contain
uniqu
complementaritydetermin
region
cdr
sequenc
select
convers
fulllength
antibodi
clone
gene
encod
human
constant
region
express
mammalian
cell
humanmacaqu
chimer
mab
total
demonstr
strong
neutral
activ
three
clade
virus
use
plaquereduct
assay
virus
analysi
select
three
mab
repres
differ
famili
vh
vl
figur
notabl
mab
contain
somewhat
longer
measur
amino
acid
residu
vh
demonstr
similar
human
famili
wherea
vh
close
resembl
human
famili
immunofluoresc
analysi
confirm
bind
three
mab
virus
cell
infect
three
clade
recombin
virus
exhibit
reactiv
viru
figur
western
blot
analysi
demonstr
mab
react
fragment
three
demonstr
reactiv
region
figur
western
blot
mab
demonstr
reactiv
ha
protein
indic
mab
like
bind
conform
epitop
ha
influenza
viral
ha
protein
mediat
viral
entri
two
step
attach
step
ha
bind
sialic
acid
cell
surfac
receptor
viru
endocytos
cell
postattach
step
acidif
endosom
induc
conform
chang
ha
lead
releas
viral
rna
subsequ
replic
first
use
microneutr
assay
determin
neutral
activ
mab
recombin
influenza
virus
tabl
mab
demonstr
crossclad
neutral
activ
virus
viru
mab
exhibit
inhibit
potenc
less
clade
clade
virus
moder
potenc
clade
viru
mab
demonstr
inhibit
clade
viru
clade
clade
virus
perform
hemagglutin
inhibit
hai
assay
three
mab
tabl
result
indic
block
bind
virion
cell
surfac
receptor
wherea
like
affect
postattach
process
taken
togeth
western
blot
immunofluoresc
analys
data
suggest
like
bound
epitop
globular
head
ha
wherea
bound
conform
epitop
associ
cell
receptor
bind
import
postattach
step
next
measur
affin
humanmacaqu
chimer
mab
ha
protein
surfac
plasmon
reson
spr
assay
use
biacor
instrument
figur
particular
mab
exhibit
extrem
high
affin
pm
extrem
slow
dissoci
rate
ha
protein
avietnam
mab
exhibit
high
affin
nm
ha
protein
mab
contain
somewhat
longer
amino
acid
might
contribut
high
affin
slow
dissoci
rate
ha
protein
exhibit
extrem
high
affin
ha
potent
neutral
activ
perform
studi
identifi
bind
site
ha
escap
mutant
gener
incub
presenc
low
concentr
figur
data
demonstr
mutat
aspart
asparagin
n
amino
acid
posit
lysin
k
glutam
e
amino
acid
posit
globular
head
result
escap
neutral
furthermor
escap
mutant
show
respons
hai
concentr
could
complet
block
hemagglutin
bioinformat
analysi
demonstr
two
amino
acid
highli
conserv
among
major
virus
virus
contain
contain
isoelectr
therefor
appear
broadli
neutral
antibodi
may
neutral
major
virus
studi
requir
verifi
neutral
contain
k
r
associ
rate
ka
dissoci
rate
kd
affin
constant
k
evalu
use
biacor
evalu
softwar
use
langmuir
bind
mass
transfer
model
assess
degre
human
mab
analyz
amino
acid
sequenc
macaqu
framework
region
reveal
high
degre
homolog
human
immunoglobulin
gene
use
germlin
index
gi
comparison
http
domaingapaligncgi
three
mab
score
within
rang
humanderiv
mab
comparison
made
use
two
human
mab
clone
individu
infect
influenza
viru
vh
region
human
mab
exhibit
gi
valu
wherea
vh
region
macaqu
mab
exhibit
gi
valu
tabl
furthermor
humanmacaqu
chimer
mab
contain
human
igg
constant
region
overal
human
homolog
chimer
mab
greater
tabl
therefor
reason
describ
humanmacaqu
chimer
mab
humanlik
highli
homolog
human
antibodi
evalu
whether
humanlik
mab
confer
protect
vivo
investig
therapeut
efficaci
mab
balbc
mice
infect
lethal
dose
viru
mab
exhibit
differ
bind
kinet
ha
protein
neutral
via
differ
mechan
mice
first
infect
intranas
ld
viru
hour
hour
hour
postinfect
mice
administ
singl
intraperiton
inject
mgkg
figur
contrast
mice
receiv
hour
hour
postinfect
protect
protect
mice
treat
hour
postinfect
moreov
mice
treat
exhibit
signific
decreas
bodi
weight
infect
figur
qpcr
analysi
lung
tissu
demonstr
mice
treat
exhibit
log
reduct
viral
genom
copi
number
compar
control
iggtreat
group
figur
strikingli
none
mice
treat
mab
detect
live
viru
lung
day
postinfect
comparison
mice
receiv
control
igg
exhibit
pfu
live
viru
per
lung
wherea
mab
mice
detect
reduc
log
reduct
live
virus
lung
figur
result
suggest
mab
exhibit
extrem
potent
neutral
activ
complet
inhibit
viru
histopatholog
examin
demonstr
visibl
patholog
chang
lung
mice
treat
hour
postinfect
wherea
control
group
receiv
irrelev
igg
exhibit
sever
alveolar
damag
interstiti
inflammatori
infiltr
immunohistochem
stain
lung
cryostat
section
mab
influenza
nucleoprotein
np
demonstr
strong
express
np
cytoplasm
pulmonari
alveolar
epitheli
cell
mice
receiv
control
igg
mice
treat
figur
mab
although
impress
mab
also
demonstr
high
potenc
protect
mice
viral
load
reduct
lung
confer
protect
mice
treat
hour
lethal
infect
taken
togeth
data
suggest
mab
exhibit
vivo
therapeut
efficaci
viru
similar
sever
report
mab
wherea
mab
repres
uniqu
mab
superior
potenc
inhibit
viru
proofofconcept
studi
gener
humanmacaqu
chimer
mab
exhibit
high
homolog
human
antibodi
high
affin
potent
neutral
activ
humanlik
mab
repres
potenti
solut
meet
urgent
need
outbreak
new
influenza
pandem
virul
infecti
diseas
humanlik
mab
good
altern
event
virul
infecti
outbreak
especi
human
survivor
infect
ethic
regulatori
issu
aris
prevent
immun
individu
antigen
pathogen
strategi
overal
process
use
studi
ie
immun
rhesu
macaqu
use
adenovir
vector
carri
synthet
gene
encod
antigen
follow
rapid
select
mab
use
immunefocus
antibodi
phage
display
librari
mab
clone
technolog
great
practic
use
signific
overal
process
could
complet
approxim
two
month
entail
follow
five
major
step
figur
immun
rhesu
macaqu
day
collect
pbmc
earli
day
day
booster
immun
necessari
construct
immun
antibodi
phage
display
librari
select
neutral
clone
could
complet
approxim
one
week
clone
variou
region
macaqu
antibodi
express
plasmid
contain
human
immunoglobulin
constant
region
could
complet
number
day
product
character
chimer
mab
could
take
week
month
howev
import
understand
mab
test
human
preclin
studi
safeti
toxic
test
includ
screen
selfantigen
need
uniqu
advantag
gener
antigenspecif
neutral
antibodi
therapeut
prophylact
use
immun
rhesu
macaqu
compar
mice
anim
speci
homolog
rhesu
human
immunoglobulin
gene
high
recent
analysi
confirm
averag
homolog
correspond
rhesu
vh
human
vh
gene
approxim
studi
gener
chimer
antibodi
contain
macaqu
vh
vl
combin
human
immunoglobulin
constant
region
increas
degre
human
fulllength
antibodi
greater
much
higher
humanmous
chimer
antibodi
sever
humanmous
chimer
antibodi
market
contain
murinederiv
vh
vl
humanderiv
constant
region
infliximabremicad
rituximabrituxan
cetuximaberbitux
antiegfr
basiliximabsimulect
howev
approxim
humanmous
chimer
antibodi
encount
signific
human
antiantibodi
respons
patient
compar
human
antibodi
humanmacaqu
chimer
antibodi
suitabl
applic
human
highli
homolog
human
antibodi
less
like
induc
human
antichimer
antibodi
humanmous
chimer
antibodi
concept
support
report
least
two
humanmacaqu
chimer
mab
galiximab
lumiliximab
vh
vl
cynomolg
macaqu
fuse
human
constant
region
phase
ii
clinic
studi
human
antigaliximab
antilumiliximab
antibodi
detect
human
final
need
would
easier
chang
small
number
amino
acid
framework
region
macaqu
vh
vl
region
produc
complet
germlin
human
howev
believ
chang
would
like
unnecessari
framework
region
mab
within
rang
human
compar
human
counterpart
use
influenza
viru
model
demonstr
humanlik
mab
exhibit
high
affin
subpicomolar
nanomolar
level
high
neutral
potenc
could
gener
use
simpl
method
base
publish
inform
regard
human
mab
viru
compar
mab
k
pm
mab
exhibit
highest
affin
k
pm
mab
demonstr
slow
dissoci
rate
ha
protein
interestingli
contain
somewhat
longer
region
consist
amino
acid
report
human
mab
influenza
viru
ha
contain
amino
acid
compar
data
publish
data
sever
mab
human
origin
test
mous
model
corti
et
al
describ
two
heterosubtyp
mab
howev
antibodi
test
prophylact
mous
model
surviv
rate
respect
observ
use
mgkg
bodi
weight
simmon
et
al
identifi
three
mab
demonstr
therapeut
protect
mice
infect
administ
higher
dosag
mgkg
bodi
weight
sui
et
al
identifi
sever
broadspectrum
mab
exhibit
affin
pm
pm
pm
respect
mab
demonstr
therapeut
protect
administ
mgkg
bodi
weight
wherea
poorli
effect
therapeut
model
howev
mabtreat
mice
pfu
live
viru
detect
per
gram
lung
tissu
treat
group
de
marco
et
al
identifi
human
mab
recogn
highli
conserv
epitop
stem
region
ha
exhibit
broad
spectrum
neutral
subtyp
howev
mgkg
dose
administ
hour
postinfect
afford
protect
mice
infect
compar
report
mab
demonstr
mab
least
among
best
mab
report
literatur
exhibit
vivo
therapeut
efficaci
viru
addit
indistinguish
differ
degre
human
mab
human
origin
confer
protect
mice
hour
infect
protect
mice
hour
infect
furthermor
singl
treatment
complet
inactiv
viru
treat
group
specul
extrem
slow
dissoci
rate
ha
bind
epitop
may
play
role
impress
potenc
mab
base
data
escap
mutant
bound
conserv
site
globular
head
ha
amino
acid
present
virus
singl
mutat
ha
diminish
bind
therefor
viru
would
need
two
mutat
escap
neutral
taken
togeth
studi
demonstr
prepared
outbreak
virul
infecti
diseas
futur
humanlik
neutral
mab
exhibit
high
affin
high
potenc
could
gener
readili
immunefocus
antibodi
phage
display
librari
deriv
rhesu
macaqu
immun
target
antigen
altern
mab
could
select
singl
b
cell
antibodysecret
plasma
cell
asc
although
report
mab
clone
rtpcr
immunoglobulin
gene
singl
b
cell
asc
cell
isol
individu
infect
influenza
viru
receiv
influenza
vaccin
technic
requir
b
cell
manipul
requir
sophist
expertis
laboratori
equip
may
readili
avail
especi
develop
countri
summari
demonstr
practic
option
obtain
highaffin
highpot
neutral
mab
urgent
need
may
advantag
term
effect
speed
simplic
practic
mab
describ
studi
potenti
readili
avail
human
applic
especi
midst
outbreak
virul
infecti
diseas
studi
warrant
investig
develop
protect
outbreak
new
influenza
pandem
emerg
infecti
diseas
recombin
replicationincompet
serotyp
adenovirus
carri
ha
gene
variou
virus
gener
base
homolog
recombin
describ
previous
express
cassett
contain
ha
gene
control
cmv
promot
bovin
growth
hormon
bgh
poli
signal
clone
adenovir
region
ha
sequenc
influenza
viru
obtain
influenza
sequenc
databas
wwwflulanlgov
ha
gene
optim
accord
prefer
codon
usag
optim
express
mammalian
cell
synthes
chemic
recombin
adenovirus
produc
cell
purifi
cesium
chlorid
gradient
centrifug
viral
particl
number
determin
measur
absorb
nm
viral
genom
extract
use
proteinas
k
digest
restrict
enzym
digest
pcr
use
confirm
genom
integr
express
ha
protein
confirm
western
blot
analysi
use
chicken
serum
ha
ha
gene
ahong
kong
influenza
virus
modifi
delet
polybas
amino
acid
ha
mutat
ha
sequenc
use
gener
recombin
virus
influenza
viru
apuerto
background
recombin
influenza
virus
gener
use
revers
genet
system
describ
previous
fortyeight
hour
transfect
supernat
transfect
cell
collect
inocul
allanto
caviti
embryon
chicken
egg
viru
propag
correct
sequenc
recombin
virus
confirm
nucleotid
sequenc
analysi
two
male
chines
rhesu
macaqu
age
year
immun
mixtur
three
virus
particl
viru
via
intramuscular
inject
boost
week
week
one
micro
liter
blood
rhesu
macaqu
collect
everi
two
week
plasma
antibodi
examin
anim
hous
handl
accord
guidelin
set
associ
assess
accredit
laboratori
anim
care
studi
protocol
approv
gibh
institut
anim
care
use
committe
protocol
number
step
taken
amelior
welfar
avoid
suffer
rhesu
monkey
accord
recommend
weatheral
report
use
nonhuman
primat
anim
hous
adjoin
individu
primat
cage
allow
social
interact
condit
control
humid
temperatur
light
dark
cycl
food
water
avail
ad
libitum
anim
monitor
daili
fed
commerci
monkey
chow
treat
fruit
twice
daili
train
personnel
environment
enrich
consist
commerci
toy
procedur
includ
immun
blood
draw
perform
sedat
train
personnel
supervis
veterinarian
rhesu
monkey
good
condit
rehous
experi
primer
use
amplifi
rhesu
macaqu
heavychain
lightchain
variabl
region
design
base
previou
public
rhesu
macaqu
immunoglobulin
gene
sequenc
sequenc
group
h
h
famili
accord
imgt
nomenclatur
base
nucleotid
sequenc
align
individu
famili
design
set
primer
target
conserv
motif
framework
region
join
constant
region
hand
lchain
gene
design
revers
primer
heavi
chain
analyz
separ
sequenc
forward
primer
heavi
chain
focus
sequenc
six
ighj
gene
base
report
macaqu
lightchain
sequenc
design
primer
igkv
subgroup
iglv
subgroup
primer
sequenc
degener
number
posit
maxim
amplif
effici
minim
creation
stop
codon
blood
sampl
ml
collect
rhesu
macaqu
peripher
blood
b
lymphocyt
isol
use
optiprep
axisshield
norway
mrna
extract
lymphocyt
use
qiagen
blood
rna
kit
qiagen
reversetranscrib
use
primer
specif
rhesu
macaqu
igg
constant
region
clone
vh
vl
dna
fragment
pcantab
phage
display
vector
perform
describ
previous
librari
pan
recombin
ha
protein
two
round
phage
pan
individu
clone
enrich
phage
pool
analyz
use
elisa
influenza
virus
posit
clone
sequenc
determin
heavyand
lightchain
sequenc
sequenc
analyz
use
intern
immunogenet
inform
system
imgt
http
imgtcinesfr
compar
sequenc
human
immunoglobulin
gene
select
scfv
convert
fulllength
antibodi
clone
vh
vl
sequenc
infram
human
constant
region
hc
lc
express
plasmid
express
light
chain
heavi
chain
separ
express
vector
modifi
base
backbon
pgineo
vector
equal
molar
amount
heavychain
plasmid
lightchain
plasmid
cotransfect
cell
transient
express
supernat
harvest
four
day
transfect
igg
purifi
affin
chromatographi
use
protein
mdck
cell
grown
monolay
glass
slide
plate
infect
recombin
virus
moi
hour
postinfect
cell
fix
use
freshli
prepar
paraformaldehyd
minut
permeabil
use
pb
contain
triton
min
room
temperatur
cell
block
pb
contain
bsa
hour
incub
mous
antinp
primari
antibodi
mab
pb
contain
bsa
hour
bound
antibodi
detect
use
antimous
igg
secondari
antibodi
fitcconjug
antihuman
igg
secondari
antibodi
confoc
microscopi
leica
germani
neutral
antibodi
titer
determin
essenti
describ
previous
brief
influenza
viru
tcid
incub
twofold
dilut
purifi
igg
hour
plate
contain
mdck
cell
monolay
incub
virusantibodi
sampl
remov
well
cell
incub
day
minim
essenti
medium
contain
bovin
albumin
neutral
titer
defin
highest
dilut
antibodi
hai
assay
perform
use
standard
method
describ
previous
briefli
influenza
viru
strain
ha
titer
ha
unit
mix
twofold
dilut
purifi
igg
pb
vbottom
plate
minut
incub
room
temperatur
chicken
erythrocyt
ad
mixtur
plate
maintain
room
temperatur
minut
hai
titer
defin
highest
dilut
plasma
purifi
mab
inhibit
hemagglutin
kinet
analys
mab
bind
recombin
monom
perform
biacor
devic
biacor
sweden
antihuman
igg
fc
antibodi
biacor
coval
attach
individu
flow
cell
surfac
sensor
chip
amin
coupl
use
amin
coupl
kit
biacor
ha
mab
captur
antihuman
fc
surfac
ha
protein
inject
flow
cell
hbsep
buffer
flow
rate
concentr
nm
experi
includ
addit
antihuman
igg
fc
antibodi
control
surfac
account
chang
refract
index
buffer
test
potenti
nonspecif
interact
ha
antihuman
igg
fc
reson
unit
ru
reflect
concentr
antibodyantigen
complex
associ
rate
ka
dissoci
rate
kd
affin
constant
k
calcul
use
biacor
evalu
softwar
use
langmuir
bind
model
mass
transfer
global
analysi
method
qualiti
fit
base
agreement
experiment
data
calcul
fit
chi
valu
escap
mutant
select
describ
previous
modif
brief
pfu
hiu
hemagglutin
inhibit
unit
incub
h
overnight
virusantibodi
mixtur
inocul
embryon
chicken
egg
allanto
fluid
harvest
h
incub
plaqu
purifi
singl
isol
plaqu
select
amplifi
embryon
chicken
egg
presenc
antibodi
escap
mutant
harvest
test
use
hai
assay
mn
assay
follow
genom
sequenc
western
blot
analysi
therapeut
protect
experi
perform
previous
report
femal
balbc
mice
week
old
hous
accredit
biosafeti
level
anim
facil
accord
protocol
approv
hku
anim
care
use
committe
anim
lost
start
bodi
weight
end
experi
sacrif
via
co
inhal
inocul
mice
tissu
harvest
perform
biosafeti
cabinet
personnel
wear
power
air
purifi
respir
therapeut
efficaci
studi
mice
per
group
inocul
intranas
viru
volum
variou
time
infect
singl
inject
mab
administ
via
intraperiton
inject
volum
ml
human
igg
use
neg
control
inject
hour
infect
determin
viral
load
infect
lung
mice
group
sacrif
day
postinfect
right
lung
collect
homogen
ml
cold
mem
viru
titer
clarifi
lung
homogen
determin
use
plaqu
assay
mdck
cell
realtim
pcr
detect
left
lung
fix
histopatholog
analysi
remain
mice
group
monitor
weigh
daili
day
infect
lung
fix
immedi
buffer
formalin
embed
paraffin
wax
thick
section
mount
slide
follow
h
e
stain
histopatholog
chang
analyz
light
microscop
describ
lung
section
stain
describ
use
antiinfluenza
nucleoprotein
mab
atcc
dilut
goat
antimous
igg
h
l
chainspecif
biotin
conjug
calbiochem
dilut
streptavidinperoxidas
complex
reagent
vector
laboratori
figur
mab
bind
conserv
epitop
ha
globular
head
western
blot
analysi
purifi
virion
escap
mutant
sampl
blot
antinp
monoclon
antibodi
respect
b
structur
ha
protein
bind
site
ha
highlight
red
yellow
c
protein
sequenc
align
residu
number
ha
virus
use
studi
clade
clade
protein
sequenc
align
residu
number
ha
wildtyp
virus
test
vitro
assay
studi
escap
mutant
tif
tabl
analysi
rhesu
human
base
germlin
index
gi
gi
number
ident
framework
amino
acid
total
number
framework
amino
acid
fulli
human
mab
influenza
virus
report
previous
literatur
gi
valu
achiev
onlin
analysi
http
domaingapaligncgi
docx
tabl
align
rhesu
macaqu
heavi
chain
light
chain
variabl
region
closest
human
germlin
gene
amino
acid
sequenc
heavi
chain
light
chain
variabl
region
compar
closest
human
germlin
counterpart
fulllength
humanmacaqu
chimer
mab
also
compar
docx
advic
cours
studi
suffer
cancer
never
gave
fight
end
acknowledg
zheng
xuehua
zhang
beiwu
li
zhixia
guo
haijiang
technic
assist
staff
gibh
anim
center
support
care
anim
throughout
studi
